drugset / Trial / NCT04800822
PF-07284892 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.
Timeline
- Start
- 2021-03-17
- Primary completion
- 2024-06-19
- Completion
- 2024-06-19
Outcome
Outcome not reported
Stopped (Business): “The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Encorafenib | Small molecule | — | — |
| Subject | Lorlatinib | Small molecule | — | — |
| Subject | PF-07284892 | Small molecule | — | — |